CLCN7

Across TCGA pan-cancer cohorts, CLCN7 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CLCN7 data layer compared with 19 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CLCN7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CLCN7 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where CLCN7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	II,III,IV	0.794	0.991	.002	28	view →
CCRCC	DFS	Median	III,IV	0.105	0.928	.003	24	view →
HNSC	OS	Tertile	IV	0.722	0.870	.034	2	view →
LUAD	OS	Quartile	III,IV	1.000	0.513	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CLCN7–PDAC (OS)

Open the PDAC breakdown →